Bambusa Therapeutics Inc. Announces Successful Series Seed Funding to Advance Innovative Bispecific Antibodies for Immunology & Inflammation
Bambusa Therapeutics Inc. Announces Successful Series Seed Funding to Advance Innovative Bispecific Antibodies for Immunology & Inflammation
"We founded Bambusa Therapeutics with a belief that the I&I field is long overdue for innovative approaches and transformative therapeutics. Since our inception, we have built a diverse portfolio of molecules and is uniquely positioned to make significant contributions to patients suffering from debilitating and chronic inflammatory conditions," said Dr. BOSTON, Sept. 9, 2024 /PRNewswire/ -- Bambusa Therapeutics Inc., a biotechnology company focused on developing bispecific antibodies for the treatment of immunological and inflammatory (I&I) disorders, announced the successful closing of its Series Seed financing round, raising approximately $15 million.
波士頓，2024年9月9日 /PRNewswire/ — 專注於開發用於治療免疫和炎症（I&I）疾病的雙特異性抗體的生物技術公司Bambusa Therapeutics Inc. 宣佈成功完成其系列種子輪融資，籌集了約1500萬美元。
Bambusa Therapeutics was founded by a team of industry experts and scientific innovators united by a vision to transform the treatment landscape for I&I diseases. The company leverages validated targets to create bispecific antibody therapeutics through innovative antibody engineering, with an aim to achieve best-in-disease profiles for multiple indications.
Bambusa Therapeutics由一支由行業專家和科學創新者組成的團隊創立，他們的願景是改變I&I疾病的治療格局。該公司利用經過驗證的靶點，通過創新的抗體工程開發雙特異性抗體療法，旨在爲多種適應症實現最佳病情特徵。
The financing round was co-led by BVF Partners L.P. and Dawn Biopharma, a platform controlled by KKR, with participation from Salvia GmbH and INCE Capital. The capital raised will be used to accelerate the development of Bambusa Therapeutics Inc.'s promising pipeline of bispecific antibodies to Phase I clinical studies.
本輪融資由BVF Partners L.P. 和由KKR控制的平台Dawn Biopharma共同牽頭，Salvia GmbH和INCE Capital也參與其中。籌集的資金將用於加速Bambusa Therapeutics Inc.的發展。”具有前景的I期臨床研究雙特異性抗體產品線。
"We founded Bambusa Therapeutics with a belief that the I&I field is long overdue for innovative approaches and transformative therapeutics. Since our inception, we have built a diverse portfolio of molecules and is uniquely positioned to make significant contributions to patients suffering from debilitating and chronic inflammatory conditions," said Dr. Shanshan Xu, CEO and Co-Founder of Bambusa Therapeutics.
“我們創立Bambusa Therapeutics時堅信創新方法和變革性療法早就該進入I&I領域了。Bambusa Therapeutics首席執行官兼聯合創始人徐珊珊博士說，自成立以來，我們已經建立了多元化的分子組合，處於獨特的地位，可以爲患有虛弱性和慢性炎症的患者做出重大貢獻。
Helmut Jeggle, Managing Director of Salvia GmbH and Co-Founder of Bambusa Therapeutics, commented, "We are thrilled to have the support of such distinguished investors who share our vision. This funding will allow us to strengthen the team to advance our lead candidates through preclinical development and position us for success in clinical studies."
Salvia GmbH董事總經理兼Bambusa Therapeutics聯合創始人赫爾穆特·傑格爾評論說：「我們很高興得到這些與我們有着共同願景的傑出投資者的支持。這筆資金將使我們能夠加強團隊，通過臨床前開發推動我們的主要候選人發展，併爲我們在臨床研究中取得成功做好準備。」
About Bambusa Therapeutics Inc.:
關於 Bambusa Therapeutics Inc.：
Bambusa Therapeutics is a rapidly growing biotechnology company specializing in developing transformative inflammatory and immunological therapeutics. Based in the vibrant Boston Seaport area, our mission is to advance the field of immunology with cutting-edge solutions.
Bambusa Therapeutics是一家快速發展的生物技術公司，專門開發變革性的炎症和免疫療法。我們的總部設在充滿活力的波士頓海港地區，我們的使命是通過尖端解決方案推動免疫學領域的發展。
SOURCE Bambusa Therapeutics
來源 Bambusa Therapeutics
譯文內容由第三人軟體翻譯。
